The Autonomous University of Madrid (UAM) and the multinational pharmaceutical company Insud Pharma are launching the UAM-Insud Pharma Programme of Innovation Challenges with a Strong Social Impact for biomedical innovation with an open innovation approach that enables the transfer of knowledge through science excellence to overcome some of the specific challenges of our society. This agreement seeks to encourage collaboration between both parties, to promote and improve research, development and innovation activities.
The challenges or demands for science and technology-based solutions for biomedical innovations were imparted to the research groups from the UAM, which proposed various preliminary solutions from a variety of scientific perspectives. Finally, Insud Pharma decided which of these to develop as individual projects through the group’s companies, Chemo, Exeltis and mAbxience.
In the area of women’s health, we are working on products for high-risk pregnancies and dietary supplements. With mAbxience, we are developing monoclonal antibody validation projects for certain diseases. We also want to develop supplements that are especially designed for adult populations.
The researchers involved are from the Faculty of Science of UAM, Mª Ángeles Martín Cabrejas from the Applied Physical Chemistry Dept. and Manuel Fresno from the Molecular Biology Dept. And from the Faculty of Medicine, Silvia Arribas and Mercedes Ferrer from the Physiology Dept.; José Luis Bartha from the Gynaecology and Obstetrics Dept. and Head of the Gynaecology Department of Hospital la Paz; Gabriel Herrero Beaumont from the Medicine Dept. and Head of the Jiménez Díaz Foundation’s Rheumatology Department ; and Benilde Jiménez-Cuenca from the Biochemistry Dept.
The UAM-Insud Pharma Programme of Innovation Challenges with a Strong Social Impact for biomedicinal innovation was launched at the Autonomous University of Madrid’s Cantoblanco Campus, where the various ecosystem actors gathered in a meeting chaired by Rafael Garesse, Vice-Chancellor of the UAM, José Manuel González, Deputy-Vice Chancellor of Research of UAM and Fidel Rodríguez Batalla, Managing Director of the UAM Foundation, who were joined by representatives from Insud Pharma, including, Carlos Romero-Camacho, Global Director of Corporate Affairs, José Miguel Rizo, Director of the OTC Division and Cédric Bes, Director of R&D at mAbxience.